Investors who want to bet on China’s booming biopharma industry will soon be able to buy and sell a new basket of securities.

A new exchange-traded fund dedicated to the sector will begin trading on the Nasdaq stock exchange on Wednesday, under the ticker CHNA. The ETF comes from the biotech investor Brad Loncar, who earlier this year launched an index tracking the performance of China’s drug industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Why aren’t you promoting investment in USA-produced pharmaceuticals & basic supplies like bandages, which are traceable & can be investigated for public health & safety issues?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy